MediGene enters clinic in melanoma

MediGene AG (NMarkt:MDG) and partner Aventis Pharma AG (AVE; NM:AVE; DAX:AVE) began Phase I/II trials in Europe of a therapeutic vaccine to treat malignant melanoma. The vaccine is based on MDG's aden...